Why Jasper Therapeutics (JSPR) Shares Are Jumping Today - Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics Inc JSPR announced data from the first three participants in a Phase 1/2 clinical trial evaluating the addition of briquilimab (JSP191) to an existing bone marrow transplantation regimen in individuals with sickle cell disease (SCD) and beta-thalassemia.
The addition of briquilimab is being studied as a potential way to achieve a higher percentage of healthy donor stem cell engraftment (donor chimerism) without increased toxicity.
Participant 1 achieved neutrophil engraftment at 12 days and platelet engraftment at 17 days after the transplant.
Participant 2 achieved neutrophil engraftment at 12 days and platelet engraftment at 10. Participant 3 achieved neutrophil engraftment at 16 days and platelet engraftment at eight days.
The first two participants with peripheral blood chimerism achieved 100% donor myeloid chimerism at 60 days post-transplant.
At five months post-transplant, the first participant treated with briquilimab has a total hemoglobin of 13.3 g/dL, which increased from 8-9 g/dL at baseline.
The lead candidate, JSP191, received fast-track designation from the FDA for severe combined immunodeficiency undergoing an allogeneic hematopoietic stem cell transplant.
Price Action: JSPR shares are up 241% at $1.65 on the last check Tuesday.
Photo Via Company

Jasper Therapeutics Shares Jump After Positive Data From Sickle Cell Disease Trial